Heron Therapeutics(HRTX)
$0.26-0.01 (-3.30%)
HRTX
Heron Therapeutics stock drug pipeline
$0.26
At close:-0.01 (-3.30%)
Want to see HRTX full AI Analyst Report?
Heron Therapeutics (HRTX) Drug Pipeline
1,672 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator | Analgesia | Phase IV | Completed | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE | Oct 25, 2023 | ― |
| Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator | Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia | Phase IV | Completed | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. | Oct 25, 2023 | ― |
| Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator | Analgesia | Phase IV | Unknown | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. | Oct 01, 2021 | ― |
| Htx-011, Bupivacaine Hcl, Luer-Lock Applicator, Vial Access Device | Postoperative Pain | Phase III | Completed | Bunionectomy Study for Postoperative Analgesia (EPOCH 1) | Sep 25, 2017 | ― |
| Htx-011, Bupivacaine Hcl, Luer-Lock Applicator, Vial Access Device | Postoperative Pain | Phase III | Completed | Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) | Jul 31, 2017 | ― |
| Htx-011, Bupivicaine Hcl, Ropivacaine | Postoperative Pain | Phase II | Completed | Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia | Jan 06, 2017 | ― |
| Htx-011, Bupivacaine Hcl Without Epinephrine | Postoperative Pain | Phase II | Completed | Phase 2B Upper Extremity Nerve Block Study | Jan 03, 2017 | ― |
| Htx-011, Zynrelef | Analgesia | Phase II | Completed | HTX-011 for Post-bunionectomy Analgesia | Jun 09, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator | Phase IV | Analgesia | Completed | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE | Oct 25, 2023 | ― |
| Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator | Phase IV | Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia | Completed | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. | Oct 25, 2023 | ― |
| Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator | Phase IV | Analgesia | Unknown | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. | Oct 01, 2021 | ― |
| Htx-011, Bupivacaine Hcl, Luer-Lock Applicator, Vial Access Device | Phase III | Postoperative Pain | Completed | Bunionectomy Study for Postoperative Analgesia (EPOCH 1) | Sep 25, 2017 | ― |
| Htx-011, Bupivacaine Hcl, Luer-Lock Applicator, Vial Access Device | Phase III | Postoperative Pain | Completed | Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) | Jul 31, 2017 | ― |
| Htx-011, Bupivicaine Hcl, Ropivacaine | Phase II | Postoperative Pain | Completed | Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia | Jan 06, 2017 | ― |
| Htx-011, Bupivacaine Hcl Without Epinephrine | Phase II | Postoperative Pain | Completed | Phase 2B Upper Extremity Nerve Block Study | Jan 03, 2017 | ― |
| Htx-011, Zynrelef | Phase II | Analgesia | Completed | HTX-011 for Post-bunionectomy Analgesia | Jun 09, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Heron Therapeutics Inc (HRTX) have in its pipeline
Heron Therapeutics HRTX is currently developing the following drugs: Ibuprofen, Acetaminophen, Htx-011, Bupivacaine Hydrochloride, Luer Lock Applicator, Htx-011, Bupivacaine Hcl, Luer-Lock Applicator, Vial Access Device, Htx-011, Bupivicaine Hcl, Ropivacaine, Htx-011, Bupivacaine Hcl Without Epinephrine, Htx-011, Zynrelef. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

